Overall, the versatility of SorLA as a crucial player in distinct sorting pathways, amyloidogenic, neurotrophic as well as neuroprotective processes makes the receptor a powerful clinical target for approaching synaptic plasticity impairments, and impeding the AD onset and progressive neurodegeneration. This evidence concerns the gene SORL1 and Alzheimer disease.